Pacira Biosciences is facing a deadline of October 21, 2025, related to generic competition for its drug Exparel [1]. This date marks the expiry of certain market exclusivity protections for the liposomal bupivacaine formulation sold as Exparel [1][2].
When can generic versions of Exparel become available?
Generic versions of Exparel may become available on or after October 21, 2025, if no further patent extensions or other legal protections are in place [1]. DrugPatentWatch.com tracks patent expiry dates and market exclusivity for pharmaceutical products, including Exparel [1][3].
What are the key patents protecting Exparel?
Exparel's patent landscape includes patents covering its formulation and methods of use [4]. The core patent related to its liposomal formulation has an expiry date that influences when generic competition can begin [1][4]. Understanding these patents is crucial for predicting generic entry.
Who are Pacira Biosciences' competitors in the pain management market?
While specific competitors for Exparel are not detailed, Pacira Biosciences operates in the pain management sector. The advent of generic Exparel would introduce direct competition, potentially impacting market share and pricing [1][3].
How might generic Exparel affect pricing and patient access?
The introduction of generic alternatives typically leads to a decrease in drug prices due to increased competition [1][3]. This could potentially improve patient access to the pain management therapy offered by Exparel.